About: Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis
Creator	Gautam, Archana Sauer, Andrew Dalia, Tarun Lahan, Shubham Mastoris, Prakash Acharya, Mbbs Ranka,
Source	MedRxiv
abstract	Background: Coronavirus disease 2019 (COVID-19) has been reported to cause worse outcomes in patients with underlying cardiovascular disease, especially in patients with acute cardiac injury, which is determined by elevated levels of high-sensitivity troponin. There is a paucity of data on the impact of congestive heart failure (CHF) on outcomes in COVID-19 patients. Methods: We conducted a literature search of PubMed/Medline, EMBASE, and Google Scholar databases from 11/1/2019 till 06/07/2020, and identified all relevant studies reporting cardiovascular comorbidities, cardiac biomarkers, disease severity, and survival. Pooled data from the selected studies were used for metanalysis to identify the impact of risk factors and cardiac biomarker elevation on disease severity and/or mortality. Results: We collected pooled data on 5,967 COVID-19 patients from 20 individual studies. We found that both non-survivors and those with severe disease had an increased risk of acute cardiac injury and cardiac arrhythmias, our pooled relative risk (RR) was - 8.52 (95% CI 3.63-19.98) (p<0.001); and 3.61 (95% CI 2.03-6.43) (p=0.001), respectively. Mean difference in the levels of Troponin-I, CK-MB, and NT-proBNP was higher in deceased and severely infected patients. The RR of in-hospital mortality was 2.35 (95% CI 1.18-4.70) (p=0.022) and 1.52 (95% CI 1.12-2.05) (p=0.008) among patients who had pre-existing CHF and hypertension, respectively. Conclusion: Cardiac involvement in COVID-19 infection appears to significantly adversely impact patient prognosis and survival. Pre-existence of CHF and high cardiac biomarkers like NT-pro BNP and CK-MB levels in COVID-19 patients correlates with worse outcomes. Keywords: Acute cardiac injury; cardiac arrhythmia; mortality risk; cardiac biomarkers, COVID-19.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1101/2020.07.06.20147421
has license	medrxiv
sha1sum (hex)	4c5f489a952fd3ff3cc5fd6dec56c2aff5ae0dc2
schema:url	https://doi.org/10.1101/2020.07.06.20147421
resource representing a document's title	Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis
resource representing a document's body	covid:4c5f489a952fd3ff3cc5fd6dec56c2aff5ae0dc2#body_text
is schema:about of	named entity 'data' named entity 'Biomarkers' named entity 'Systematic' named entity 'Review' named entity 'COVID-19' named entity 'patients' named entity 'COVID-19' named entity 'Coronavirus disease 2019' named entity 'Congestive Heart Failure' named entity 'COVID' named entity 'Meta-Analysis' named entity 'Cardiac Biomarkers' named entity 'pericytes' named entity 'COVID' named entity 'COVID-19' named entity 'ACE 2' named entity 'diabetes mellitus' named entity 'angiotensin II' named entity 'CC-BY-NC-ND 4.0' named entity 'statistically significant' named entity 'medRxiv' named entity 'cardiac rhythm' named entity 'CHF' named entity 'COVID-19' named entity 'alveolar epithelial cells' named entity 'Coronavirus' named entity 'CHF' named entity 'systematic review' named entity 'medRxiv' named entity 'ICU' named entity 'medRxiv' named entity 'NT-proBNP' named entity 'ACE2' named entity 'infection' named entity 'CHF' named entity '95% CI' named entity 'meta-analysis' named entity 'COVID' named entity 'angiotensin converting enzyme' named entity 'COVID' named entity 'medRxiv' named entity 'Relative risk' named entity 'cardiac biomarkers' named entity 'CHF' named entity 'PubMed' named entity 'COVID' named entity 'Severe Acute Respiratory Syndrome Coronavirus 2' named entity 'cardiac conditions' named entity 'CVD' named entity 'lactate dehydrogenase' named entity 'prognosis' named entity 'arrhythmias' named entity 'medRxiv' named entity 'effect size' named entity 'exact mechanism' named entity 'COVID-19' named entity 'cytokine storm' named entity 'medRxiv' named entity 'comorbidities' named entity 'case reports' named entity 'regression model' named entity 'COVID' named entity 'pneumonia' named entity 'CHF' named entity 'comorbidities' named entity 'COVID' named entity 'angiotensin converting enzyme 2' named entity 'medRxiv' named entity 'apoptosis' named entity 'inflammatory' named entity 'COVID' named entity 'meta-analyses' named entity 'COVID-19' named entity 'in-vivo' named entity 'fulminant' named entity 'sepsis' named entity 'COVID-19' named entity 'protein' named entity 'peer review'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software